StreetAlpha.app
Home › Stocks › NRXP

NRX Pharmaceuticals, Inc. (NRXP)

$2.45
▲ +13.95%
LAST CLOSE · NOV 17

NRx Pharmaceuticals develops ketamine-based and other drugs for central nervous system disorders such as depression and PTSD. It last closed at $2.45 on Nov 17, up 13.95% on the day. NRXP last reported earnings on Fri, Nov 13, 2026. The average 12-month price target from 2 analysts is $31.50 (+1185.7% from the last close), with a high of $51.00 and a low of $12.00.

AI Auto Pilots
Is NRXP in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.3M
+1681.4% vs a year ago
Net income
−$19.8M
−458.5% margin
EPS (diluted)
−$0.33
Gross margin
40.0%
$1.7M gross profit
Valuation
Market cap
$108.6M
44.3M shares
P/E
–
No P/E while losing money
Price to sales
25.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$19.8M
At Sep 30
Shareholder equity
−$2.0M
Shares outstanding
44.3M
At Nov 16
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $1.2M$1.2MFY2025

From NRXP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 13
2026 · Before the open (BMO)
Reported EPS
-$0.18
vs -$0.09 est. · miss
Year-ago EPS
-$0.51
Same quarter last year
Options-implied move
±22.2%
Priced in before that report
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated NRXP in the past 90 days, not enough for a consensus
Average 12-month target
$31.50
▲ 1185.7% upside

Based on 2 analysts who set a price target on NRXP in the past 90 days. The average target is $31.50, with a high of $51.00 and a low of $12.00, compared with the last close of $2.45.

Low $12.00Avg $31.50High $51.00
Blue marker: last close $2.45
Highest target$51.00
Average target$31.50
Lowest target$12.00
Latest rating changes
BTIGTarget raised
Nov 12Buy$10 → $12
Ascendiant CapitalTarget raised
Nov 2Buy$50 → $51
Ascendiant CapitalMaintained
Oct 1Buy$50
BTIGReiterated
Aug 18Buy$10
BTIGMaintained
Aug 7Buy$10
DateFirmActionRatingPrice target
Nov 12BTIGTarget raisedBuy$10 → $12
Nov 2Ascendiant CapitalTarget raisedBuy$50 → $51
Oct 1Ascendiant CapitalMaintainedBuy$50
Aug 18BTIGReiteratedBuy$10
Aug 7BTIGMaintainedBuy$10
Loading…

Technical Analysis

NRXP · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 21% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the 20 day average at $2.41, and the nearest resistance the swing high (Nov 11) at $2.50.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 8.2%/day
Key levels
$5.0652 week high+106.5%
$3.23100 day average+31.8%
$2.98200 day average+21.6%
$2.7750 day average+13.1%
$2.57Pivot R1+4.9%
$2.50Swing high (Nov 11)+2.0%
$2.45Last close
$2.4120 day average−1.6%
$2.34Pivot−4.5%
$2.24Swing low (Oct 23)−8.6%
$2.22Pivot S1−9.4%
$1.6252 week low−33.9%
Indicators
RSI (14)48.32Middle of its rangeNeutral
MACD-0.14Above its signal lineBullish
Stochastic24.6Middle of its rangeNeutral
ADX (14)32.6Trending down
Williams %R-49.5Oversold below −80, overbought above −20Neutral
CCI (20)-38.3Oversold below −100, overbought above 100Neutral
Rate of change+9.4%Change over 10 sessionsBullish
ATR (14)$0.20Typical daily range, 8.2% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for NRXP

What happened before

See how NRXP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NRXP usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NRXP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NRXP in the last 90 days.

Loading…

See today’s whale options flow across the market →

NRXP Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲36 buying vs 15 selling
  • ▲Held by funds +5.7 pts
  • ▲Funds holding +3
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5047+6.4%
In funds' top 10110.0%
Held by funds32.0%26.3%+5.7 pts
New / increased12 / 2418 / 17+2.9%
Reduced / sold out6 / 93 / 7+50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NRXP institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NRXP is in one of them and how their past NRXP trades turned out.

NRXP in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NRXP in an article yet. Here's the latest on the wider market.

About NRX Pharmaceuticals

NRx Pharmaceuticals is a drug developer based in Wilmington, Delaware, focused on treatments for central nervous system disorders such as depression, post traumatic stress disorder, chronic pain and schizophrenia. Its lead product candidates are ketamine formulations, including a generic version called KETAFREE, and NRX-101, a combination of D-cycloserine and lurasidone, all still awaiting approval from the U.S. Food and Drug Administration. Through its majority owned subsidiary HOPE Therapeutics, the company also runs clinics in Florida that offer interventional psychiatry care to patients with treatment resistant depression and PTSD.

Headquarters
Wilmington, DE